Halozyme Therapeutics, Inc. $HALO Position Boosted by Hsbc Holdings PLC

Hsbc Holdings PLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1,202.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 82,323 shares of the biopharmaceutical company’s stock after buying an additional 76,002 shares during the period. Hsbc Holdings PLC’s holdings in Halozyme Therapeutics were worth $5,584,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HALO. Measured Wealth Private Client Group LLC lifted its position in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Harbour Investments Inc. raised its holdings in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares in the last quarter. Clearstead Advisors LLC boosted its position in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new stake in Halozyme Therapeutics during the third quarter valued at $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $55,088,215. This represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,102 shares of company stock worth $5,205,798 in the last quarter. 2.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Morgan Stanley dropped their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Down 2.2%

Shares of Halozyme Therapeutics stock opened at $78.62 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $55.64 and a 12-month high of $82.26. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock has a 50 day moving average price of $70.63 and a two-hundred day moving average price of $69.87. The stock has a market capitalization of $9.33 billion, a P/E ratio of 28.28, a PEG ratio of 0.33 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 earnings per share. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.